The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study comparing trabectedin (T) and best supportive care (BSC) in patients (pts) with translocation-related sarcomas (TRS).
Shunji Takahashi
No relevant relationships to disclose
Nobuhito Araki
No relevant relationships to disclose
Hideshi Sugiura
No relevant relationships to disclose
Takafumi Ueda
Consultant or Advisory Role - Daiichi Sankyo
Honoraria - GlaxoSmithKline
Research Funding - Eisai; GlaxoSmithKline; Taiho Pharmaceutical
Mitsuru Takahashi
No relevant relationships to disclose
Hideo Morioka
No relevant relationships to disclose
Tsukasa Yonemoto
No relevant relationships to disclose
Hiroaki Hiraga
No relevant relationships to disclose
Toru Hiruma
No relevant relationships to disclose
Toshiyuki Kunisada
No relevant relationships to disclose
Akihiko Matsumine
No relevant relationships to disclose
Akira Kawai
Honoraria - Eisai; GlaxoSmithKline; MSD; Taiho Pharmaceutical